doi:10.48130/vns-0026-0008

[1]

Toosy AT, Mason DF, Miller DH. 2014. Optic neuritis. The Lancet Neurology 13(1):83−99

[2]

Braithwaite T, Subramanian A, Petzold A, Galloway J, Adderley NJ, et al. 2020. Trends in optic neuritis incidence and prevalence in the UK and association with systemic and neurologic disease. JAMA Neurology 77(12):1514−1523

doi: 10.1001/jamaneurol.2020.3502

[3]

Ishikawa H, Kezuka T, Shikishima K, Yamagami A, Hiraoka M, et al. 2019. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology 126(10):1385−1398

doi: 10.1016/j.ophtha.2019.04.042

[4]

The Optic Neuritis Treatment Trial Headquarters. 1991. The clinical profile of optic neuritis: experience of the optic neuritis treatment trial. Archives of Ophthalmology 109(12):1673−1678

doi: 10.1001/archopht.1991.01080120057025

[5]

Bennett JL, Costello F, Chen JJ, Petzold A, Biousse V, et al. 2023. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. The Lancet Neurology 22(1):89−100

doi: 10.1016/S1474-4422(22)00187-9

[6]

Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, et al. 2022. Diagnosis and classification of optic neuritis. The Lancet Neurology 21(12):1120−1134

doi: 10.1016/S1474-4422(22)00200-9

[7]

Sepulveda M, Delgado-García G, Blanco Y, Sola-Valls N, Martinez-Lapiscina EH, et al. 2019. Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. Neurology Neuroimmunology & Neuroinflammation 6(6):e607

doi: 10.1212/nxi.0000000000000607

[8]

Thongmee W, Narongkhananukul C, Padungkiatsagul T, Jindahra P, Vanikieti K. 2021. Comparison of early- and late-onset NMOSD-related optic neuritis in Thai patients: clinical characteristics and long-term visual outcomes. Clinical Ophthalmology 15:419−429

doi: 10.2147/OPTH.S295769

[9]

Netravathi M, Holla VV, Nalini A, Yadav R, Vengalil S, et al. 2021. Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. Journal of Neurology 268(4):1419−1433

doi: 10.1007/s00415-020-10300-z

[10]

Nakahara K, Nakane S, Nagaishi A, Narita T, Matsuo H, et al. 2021. Very late onset neuromyelitis optica spectrum disorders. European Journal of Neurology 28(8):2574−2581

doi: 10.1111/ene.14901

[11]

Rizzo JF. 1991. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Archives of Ophthalmology 109(12):1668

doi: 10.1001/archopht.1991.01080120052024

[12]

Schroeder A, Chen JJ, Van Stavern G. 2020. MOG-associated optic neuritis masquerading as NAION in an elderly woman: a case report. Multiple Sclerosis and Related Disorders 43:102142

doi: 10.1016/j.msard.2020.102142

[13]

Ayrignac X, Carra-Dallière C, Labauge P. 2020. Diagnostic and therapeutic issues of inflammatory diseases of the elderly. Revue Neurologique 176(9):739−749

doi: 10.1016/j.neurol.2020.03.014

[14]

Graves JS, Oertel FC, Van der Walt A, Collorone S, Sotirchos ES, et al. 2022. Leveraging visual outcome measures to advance therapy development in neuroimmunologic disorders. Neurology Neuroimmunology & Neuroinflammation 9(2):e1126

doi: 10.1212/nxi.0000000000001126

[15]

World Medical Association. 2025. World medical association declaration of Helsinki: ethical principles for medical research involving human participants. JAMA 333(1):71−74

doi: 10.1001/jama.2024.21972

[16]

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, et al. 2015. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177−189

doi: 10.1212/WNL.0000000000001729

[17]

López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, et al. 2018. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurology 75(11):1355−1363

doi: 10.1001/jamaneurol.2018.1814

[18]

Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, et al. 2023. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. The Lancet Neurology 22(3):268−282

doi: 10.1016/S1474-4422(22)00431-8

[19]

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, et al. 2018. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology 17(2):162−173

doi: 10.1016/S1474-4422(17)30470-2

[20]

Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. 2006. Visual acuities 'hand motion' and 'counting fingers' can be quantified with the Freiburg visual acuity test. Investigative Ophthalmology & Visual Science 47(3):1236−1240

doi: 10.1167/iovs.05-0981

[21]

Zhang LJ, Yang LN, Li T, Wang J, Qi Y, et al. 2017. Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders. The International Journal of Neuroscience 127(4):334−338

doi: 10.1080/00207454.2016.1254630

[22]

Carnero Contentti E, Daccach Marques V, Soto de Castillo I, Tkachuk V, Ariel B, et al. 2020. Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort. Journal of Neurology 267(5):1260−1268

doi: 10.1007/s00415-020-09699-2

[23]

Seok JM, Cho HJ, Ahn SW, Bin Cho E, Park MS, et al. 2017. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: a multicenter retrospective study in Korea. Multiple Sclerosis Journal 23(13):1748−1756

doi: 10.1177/1352458516685416

[24]

Santos E, Moura J, Samões R, Sousa AP, Mendonça T, et al. 2022. Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: anti-AQP4 positive, anti-MOG positive and seronegative subgroups. Multiple Sclerosis and Related Disorders 63:103845

doi: 10.1016/j.msard.2022.103845

[25]

Wang L, Tan H, Huang W, Chang X, ZhangBao J, et al. 2022. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies. European Journal of Neurology 29(4):1128−1135

doi: 10.1111/ene.15239

[26]

Shi W, Zhang HT, Zuo HX, Li SY, Zheng PP, et al. 2022. Structural-visual functional relationships detected by optical coherence tomography in varying age-cohorts' patients with optic neuritis. International Journal of Ophthalmology 15(6):967−974

doi: 10.18240/ijo.2022.06.15

[27]

Moss HE, Gao W, Balcer LJ, Joslin CE. 2014. Association of race/ethnicity with visual outcomes following acute optic neuritis: an analysis of the optic neuritis treatment trial. JAMA Ophthalmology 132(4):421−427

doi: 10.1001/jamaophthalmol.2013.7995

[28]

Wang J, Zhou H, Qin L, Peng C, Zhao J, et al. 2017. Optic neuritis in the older Chinese population: a 5-year follow-up study. Journal of Ophthalmology 2017:3458356

doi: 10.1155/2017/3458356

[29]

Zhou H, Zhao S, Yin D, Chen X, Xu Q, et al. 2016. Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. Journal of Neurology 263(7):1382−1389

doi: 10.1007/s00415-016-8155-7

[30]

Mao Z, Lu Z, Hu X. 2014. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 83(12):1122−1123

doi: 10.1212/wnl.0000000000000830

[31]

Mekhasingharak N, Laowanapiban P, Siritho S, Satukijchai C, Prayoonwiwat N, et al. 2018. Optical coherence tomography in central nervous system demyelinating diseases related optic neuritis. International Journal of Ophthalmology 11(10):1649−1656

doi: 10.18240/ijo.2018.10.12

[32]

Liu H, Zhou H, Wang J, Sun M, Teng D, et al. 2019. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. Journal of the Neurological Sciences 396:225−231

doi: 10.1016/j.jns.2018.11.029

[33]

Cai LJ, Zhang Q, Zhang Y, Chen HX, Shi ZY, et al. 2020. Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders 46:102515

doi: 10.1016/j.msard.2020.102515

[34]

Akaishi T, Nakashima I, Takeshita T, Mugikura S, Sato DK, et al. 2016. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. Journal of Neuroimmunology 293:28−33

doi: 10.1016/j.jneuroim.2016.02.004

[35]

Song H, Zhou H, Yang M, Xu Q, Sun M, et al. 2019. Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China. Journal of the Neurological Sciences 400:83−89

doi: 10.1016/j.jns.2019.03.014

[36]

Havla J, Pakeerathan T, Schwake C, Bennett JL, Kleiter I, et al. 2021. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? Journal of Neuroinflammation 18(1):121

doi: 10.1186/s12974-021-02160-9

[37]

Akaishi T, Nakashima I, Takeshita T, Kaneko K, Mugikura S, et al. 2016. Different etiologies and prognoses of optic neuritis in demyelinating diseases. Journal of Neuroimmunology 299:152−157

doi: 10.1016/j.jneuroim.2016.09.007

[38]

Hickman SJ, Petzold A. 2022. Update on optic neuritis: an international view. Neuro-Ophthalmology 46(1):1−18

doi: 10.1080/01658107.2021.1964541

[39]

Erickson MA, Banks WA. 2019. Age-associated changes in the immune system and Blood^-Brain barrier functions. International Journal of Molecular Sciences 20(7):1632

doi: 10.3390/ijms20071632

[40]

The Optic Neuritis Study Group. 1997. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology 49(5):1404−1413

doi: 10.1212/wnl.49.5.1404

[41]

The Optic Neuritis Study Group. 2008. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Archives of Neurology 65(6):727−732

doi: 10.1001/archneur.65.6.727

[42]

Feng C, Chen Q, Zhao G, Li Z, Chen W, et al. 2021. Clinical characteristics of optic neuritis phenotypes in a 3-year follow-up Chinese cohort. Scientific Reports 11:14603

doi: 10.1038/s41598-021-93976-1

[43]

Zhou L, Tan X, Wang L, Zhao X, Qiu W, et al. 2022. A longitudinal comparison of the recovery patterns of optic neuritis with MOG antibody-seropositive and AQP4 antibody-seropositive or-seronegative for both antibodies. Journal of Ophthalmology 2022(1):4951491

doi: 10.1155/2022/4951491

[44]

Fazzone HE, Lefton DR, Kupersmith MJ. 2003. Optic neuritis Correlation of pain and magnetic resonance imaging. Ophthalmology 110(8):1646−1649

doi: 10.1016/S0161-6420(03)00477-9